Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003490 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00003490 is a Phase 2 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 30 participants.
The verdict
NCT00003490, a Phase 2 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. GM-CSF may make cancer cells more sensitive to the effects of chemotherapy. Combining more than one drug with GM-CSF may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, consisting of cyclophosphamide plus vincristine, following GM-CSF in treating patients with multiple myeloma that has not responded to previous treatment.
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- BIOLOGICAL sargramostim
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1998-10 |
| Est. Completion | 2003-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003490
The ClinicalTrials.gov registry entry for NCT00003490 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which prednisone is the first listed.
NCT00003490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003490 about?
NCT00003490 is a clinical study titled "Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. GM-CSF may make cancer cells more sensitive to the effects of chemotherapy. Combining more than one drug with GM-CSF may kill more tumor cells. PURPOSE: Phase II trial to study th...
What is the current status of trial NCT00003490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1998-10. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00003490?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), sargramostim (BIOLOGICAL), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00003490?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.